Literature DB >> 8348588

Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price.

M J Underwood1, D P De Bono.   

Abstract

OBJECTIVE: The aim was to quantify and compare the fibrinolytic activity of normal blood vessels (saphenous vein, internal mammary artery, and aorta) and atheromatous arteries (coronary endarterectomy specimens).
METHODS: Fibrinolytic activity was measured by fibrin plate and colorimetric assays on fresh samples of coronary endarterectomy core, internal mammary artery, human aorta, and saphenous vein from patients undergoing coronary artery bypass surgery.
RESULTS: Fibrinolytic activity on fibrin plates ranked in the order endarterectomy cores > internal mammary artery > saphenous vein. The increased activity of endarterectomy cores was associated with an increased content of extractable tissue plasminogen activator and was suppressed by monoclonal antibody to tissue plasmogen activator. Paired comparisons of tissues from the same patients confirmed this increased activity in endarterectomy specimens relative to normal artery or vein. Urokinase activity was also increased in some endarterectomy specimens, but was more variable than tissue plasmogen activator.
CONCLUSIONS: The increased fibrinolytic activity of endarterectomy cores may help preserve patency in atheromatous vessels, but at the possible price of increased intimal instability and fibrous proliferation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348588     DOI: 10.1093/cvr/27.5.882

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  2 in total

Review 1.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1994-06

2.  Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.